Welcome to our dedicated page for Merck & Co. SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Merck & Co.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Merck & Co.'s regulatory disclosures and financial reporting.
Merck & Co. has a holder filing a notice to sell 47,434 shares of its common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney LLC, has an aggregate market value of $5,598,136.96 and is expected around 02/04/2026 on the NYSE.
The shares come from restricted stock that vested under a registered plan on 01/26/2026, in the same 47,434‑share amount. The filing also notes that 2,482,022,536 shares of Merck common stock are outstanding.
A holder of MRK common stock filed a notice of proposed resale under Rule 144. The filing covers 15087 shares of common stock with an aggregate market value of 1791824.15, to be sold through Morgan Stanley Smith Barney LLC on the NYSE around 02/04/2026.
These shares were acquired on 02/04/2026 by exercising stock options under a registered plan, with the 15087 shares paid for in cash. The filing notes that 2482022536 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
A holder of MRK common stock has filed a notice of proposed sale under Rule 144 for 41,997 shares. The shares have an aggregate market value of $5,023,311.57, and the planned sale date is February 4, 2026 on the NYSE.
The planned transaction would be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares were acquired on February 4, 2026 by exercising options under a registered plan, with the purchase price paid in cash on the same date.
Merck & Co., Inc. filed a Form 8-K to furnish information about its earnings for the fourth quarter and full year 2025. The filing references a February 3, 2026 press release attached as Exhibit 99.1 and additional supplemental information attached as Exhibit 99.2.
The company states this earnings information is being furnished under Item 2.02, not filed for liability purposes under the Exchange Act, and will only be incorporated into other filings if specifically referenced.
Merck & Co., Inc. executive Jennifer Zachary, EVP and General Counsel, reported an acquisition of 11,583 shares of common stock on January 26, 2026. The shares were distributed as net after-tax stock upon satisfying performance criteria for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over a three-year performance period ending December 31, 2025.
Following this transaction, Zachary directly holds 68,915.671 shares of Merck common stock.
Merck & Co., Inc. executive vice president and Chief Information & Digital Officer David Michael Williams received 6,112 shares of common stock on January 26, 2026 as an acquired award. These shares were distributed as net after‑tax stock upon meeting performance criteria for performance share units granted on March 31, 2023.
The performance shares were paid out at 94 percent of target awards and included dividends accrued over the three-year performance period ending December 31, 2025. Following this transaction, Williams beneficially owns 30,837.743 shares of Merck common stock, held directly and including shares acquired through dividend reinvestment.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported the acquisition of 1,066 shares of common stock on January 26, 2026. The shares were issued upon satisfaction of performance criteria for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over the three-year performance period ending December 31, 2025. Following this distribution, Smart beneficially owns 10,604.816 Merck common shares in direct ownership, including shares previously acquired through dividend reinvestment.
Merck & Co., Inc. executive Joseph Romanelli received 5,703 shares of common stock as a performance-based award. The shares were credited on January 26, 2026 at a value of $107.40 per share, increasing his directly held stake to 28,739.343 shares.
The award represents net after-tax shares distributed upon meeting performance criteria for performance share units granted on March 31, 2023. These performance shares paid out at 94% of the target award and include dividend equivalents accrued over the three-year performance period ending December 31, 2025. His holdings also include shares accumulated through dividend reinvestment.
Merck & Co., Inc. executive Johannes Jacobus Oosthuizen, President, U.S. Market, reported an automatic acquisition of 5,026 shares of common stock on January 26, 2026 at a reference price of $107.40 per share. These shares were distributed as net, after-tax stock following satisfaction of performance criteria for performance share units granted on March 31, 2023, which paid out at 94% of target and included dividends accrued over the three-year performance period ending December 31, 2025.
Following this award, Oosthuizen beneficially owns 36,197.389 shares of Merck common stock in direct ownership, and holdings also reflect shares acquired through dividend reinvestment transactions.
Merck & Co., Inc.’s EVP and CFO Caroline Litchfield reported receiving 15,852 shares of common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023.
The performance shares were paid out at 94 percent of target awards and include dividends that accrued over the three-year performance period ending December 31, 2025. Following this award, Litchfield beneficially owns 90,192.194 shares of Merck common stock directly.